Literature DB >> 28889371

Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing.

Michele Moschetta1, Yawara Kawano2, Antonio Sacco3,4, Angelo Belotti5, Rossella Ribolla5, Marco Chiarini4,6, Viviana Giustini4,7, Diego Bertoli4,7, Alessandra Sottini4,6, Monica Valotti4,6, Claudia Ghidini4,6, Federico Serana4,6, Michele Malagola8, Luisa Imberti4,6, Domenico Russo4,8, Alessandro Montanelli4,6, Giuseppe Rossi4,5, Michaela R Reagan9, Patricia Maiso10, Bruno Paiva10, Irene M Ghobrial11, Aldo M Roccaro12,13.   

Abstract

PURPOSE OF THE REVIEW: Herein we dissect mechanisms behind the dissemination of cancer cells from primary tumor site to the bone marrow, which are necessary for metastasis development, with a specific focus on multiple myeloma. RECENT
FINDINGS: The ability of tumor cells to invade vessels and reach the systemic circulation is a fundamental process for metastasis development; however, the interaction between clonal cells and the surrounding microenvironment is equally important for supporting colonization, survival, and growth in the secondary sites of dissemination. The intrinsic propensity of tumor cells to recognize a favorable milieu where to establish secondary growth is the basis of the "seed and soil" theory. This theory assumes that certain tumor cells (the "seeds") have a specific affinity for the milieu of certain organs (the "soil"). Recent literature has highlighted the important contributions of the vascular niche to the hospitable "soil" within the bone marrow. In this review, we discuss the crucial role of stromal cells and endothelial cells in supporting primary growth, homing, and metastasis to the bone marrow, in the context of multiple myeloma, a plasma cell malignancy with the unique propensity to primarily grow and metastasize to the bone marrow.

Entities:  

Keywords:  Bone marrow stroma; Bone marrow vasculature; Cancer-induced bone disease; Multiple myeloma

Mesh:

Year:  2017        PMID: 28889371     DOI: 10.1007/s11914-017-0399-3

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  87 in total

Review 1.  Angiogenesis in hematologic malignancies and its clinical implications.

Authors:  Renchi Yang; Zhong Chao Han
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

Review 2.  Angiogenesis: a target in solid tumors, also in leukemia?

Authors:  Thomas Schmidt; Peter Carmeliet
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

3.  The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma.

Authors:  Siobhan V Glavey; Salomon Manier; Alessandro Natoni; Antonio Sacco; Michele Moschetta; Michaela R Reagan; Laura S Murillo; Ilyas Sahin; Ping Wu; Yuji Mishima; Yu Zhang; Wenjing Zhang; Yong Zhang; Gareth Morgan; Lokesh Joshi; Aldo M Roccaro; Irene M Ghobrial; Michael E O'Dwyer
Journal:  Blood       Date:  2014-07-24       Impact factor: 22.113

4.  Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.

Authors:  Yu-Tzu Tai; Xian-Feng Li; Iris Breitkreutz; Weihua Song; Paola Neri; Laurence Catley; Klaus Podar; Teru Hideshima; Dharminder Chauhan; Noopur Raje; Robert Schlossman; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Cancer Res       Date:  2006-07-01       Impact factor: 12.701

Review 5.  Making sense of hematopoietic stem cell niches.

Authors:  Philip E Boulais; Paul S Frenette
Journal:  Blood       Date:  2015-03-11       Impact factor: 22.113

6.  Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistance.

Authors:  Ingrid G Winkler; Valérie Barbier; Bianca Nowlan; Rebecca N Jacobsen; Catherine E Forristal; John T Patton; John L Magnani; Jean-Pierre Lévesque
Journal:  Nat Med       Date:  2012-10-21       Impact factor: 53.440

7.  Induction of angiogenesis during the transition from hyperplasia to neoplasia.

Authors:  J Folkman; K Watson; D Ingber; D Hanahan
Journal:  Nature       Date:  1989-05-04       Impact factor: 49.962

8.  Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.

Authors:  F Di Raimondo; M P Azzaro; G Palumbo; S Bagnato; G Giustolisi; P Floridia; G Sortino; R Giustolisi
Journal:  Haematologica       Date:  2000-08       Impact factor: 9.941

9.  BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.

Authors:  Aldo M Roccaro; Antonio Sacco; Patricia Maiso; Abdel Kareem Azab; Yu-Tzu Tai; Michaela Reagan; Feda Azab; Ludmila M Flores; Federico Campigotto; Edie Weller; Kenneth C Anderson; David T Scadden; Irene M Ghobrial
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

10.  The perivascular niche regulates breast tumour dormancy.

Authors:  Cyrus M Ghajar; Héctor Peinado; Hidetoshi Mori; Irina R Matei; Kimberley J Evason; Hélène Brazier; Dena Almeida; Antonius Koller; Katherine A Hajjar; Didier Y R Stainier; Emily I Chen; David Lyden; Mina J Bissell
Journal:  Nat Cell Biol       Date:  2013-06-02       Impact factor: 28.824

View more
  9 in total

Review 1.  Extramedullary multiple myeloma.

Authors:  Manisha Bhutani; David M Foureau; Shebli Atrash; Peter M Voorhees; Saad Z Usmani
Journal:  Leukemia       Date:  2019-11-27       Impact factor: 11.528

Review 2.  Classification of Solitary Plasmacytoma, Is it more Intricate than Presently Suggested? A Commentary.

Authors:  Nissim Ohana; Ory Rouvio; Karen Nalbandyan; Dimitri Sheinis; Daniel Benharroch
Journal:  J Cancer       Date:  2018-10-10       Impact factor: 4.207

Review 3.  Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview.

Authors:  Antonella Argentiero; Antonio Giovanni Solimando; Oronzo Brunetti; Angela Calabrese; Francesco Pantano; Michele Iuliani; Daniele Santini; Nicola Silvestris; Angelo Vacca
Journal:  Cancers (Basel)       Date:  2019-08-29       Impact factor: 6.639

Review 4.  Targeted Approaches to Inhibit Sialylation of Multiple Myeloma in the Bone Marrow Microenvironment.

Authors:  Alessandro Natoni; Raghvendra Bohara; Abhay Pandit; Michael O'Dwyer
Journal:  Front Bioeng Biotechnol       Date:  2019-10-04

5.  Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse model.

Authors:  Alessandro Natoni; Mariah L Farrell; Sophie Harris; Carolyne Falank; Lucy Kirkham-McCarthy; Matthew S Macauley; Michaela R Reagan; Michael O'Dwyer
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

Review 6.  Multiple Myeloma Cell-Derived Exosomes: Implications on Tumorigenesis, Diagnosis, Prognosis and Therapeutic Strategies.

Authors:  Alessandro Allegra; Mario Di Gioacchino; Alessandro Tonacci; Claudia Petrarca; Caterina Musolino; Sebastiano Gangemi
Journal:  Cells       Date:  2021-10-24       Impact factor: 6.600

Review 7.  Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma.

Authors:  Inge Oudaert; Arne Van der Vreken; Anke Maes; Elke De Bruyne; Kim De Veirman; Karin Vanderkerken; Eline Menu
Journal:  Exp Hematol Oncol       Date:  2022-09-01

8.  C6-ceramide treatment inhibits the proangiogenic activity of multiple myeloma exosomes via the miR-29b/Akt pathway.

Authors:  Liping Liu; Qinmao Ye; Langni Liu; Ji Chen Bihl; Yanfang Chen; Jing Liu; Qian Cheng
Journal:  J Transl Med       Date:  2020-08-03       Impact factor: 5.531

9.  Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC).

Authors:  L Sanoja-Flores; J Flores-Montero; J J Garcés; B Paiva; N Puig; A García-Mateo; O García-Sánchez; A Corral-Mateos; L Burgos; E Blanco; J Hernández-Martín; R Pontes; M Díez-Campelo; P Millacoy; P Rodríguez-Otero; F Prosper; J Merino; M B Vidriales; R García-Sanz; A Romero; L Palomera; R Ríos-Tamayo; M Pérez-Andrés; J F Blanco; M González; J J M van Dongen; B Durie; M V Mateos; J San-Miguel; A Orfao
Journal:  Blood Cancer J       Date:  2018-11-19       Impact factor: 11.037

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.